Review of NICE Technology Appraisal Guidance No 124; Pemetrexed for the treatment of non-small-cell lung cancer 

The Institute was proposing that the guidance should be transferred to the static guidance list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward and that the title should include second line treatment. After consideration of all of the comments (attached as Appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal and the guidance will be transferred on to the static list.

Following on from consultation responses, a text box will be included within TA124 to make it clear that the guidance refers to second-line treatment and that there is also guidance on first-line treatment (TA181).

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.